SAN DIEGO--(BUSINESS WIRE)--Taxus Cardium Pharmaceuticals Group Inc. (OTCQB:CRXM) and its Cardium Therapeutics operating unit today presented highlights of financial results for the second quarter ended June 30, 2014.
Consistent with Taxus Cardium’s business strategy, the Company is primarily focused on the clinical and commercial development of advanced regenerative therapeutics that currently include Generx® [Ad5FGF-4], Cardium’s late-stage clinical development therapeutic angiogenesis product candidate, and the FDA-cleared Excellagen® wound care product and drug, biologic and stem cell delivery platform. Our business strategy focuses on the achievement of key milestones with the potential to enhance valuation of our core strategic product portfolio and technologies, as well as asset sales and future monetizations of the Company’s non-core investments. Activities and key accomplishments during the second quarter 2014 include the following:
Help employers find you! Check out all the jobs and post your resume.
